US dosage forms specialist Capsugel will launch its Lipidex technology platform this month (June), which integrates the firm’s lipid, liquid and semi-solid fill technologies, product development expertise, and commercial manufacturing infrastructure.
The Lipidex technology offers three encapsulation approaches, including liquid hard shell, Licaps, pictured.
Capsugel says the technology is the culmination of its acquisition of Encap earlier this year, and will enable the recently formed Capsugel Dosage Form Solutions (DFS) business unit to accelerate and improve the development of innovative products for pharmaceutical and nutraceutical customers.
The Lipidex technology includes Capsugel DFS’ clinical fast track development programme that uses the firm’s Lipid Expert System to streamline various aspects of the development process. It offers three encapsulation approaches, including a soft gel (SGcaps), liquid hard shell (Licaps) (inclusive of vegetarian options) and new solid lipid pellet technology currently under development, and which will be launched later this year.
Our Lipidex technology platform provides tailored solutions for the many challenges our customers face
‘Our Lipidex technology platform provides tailored solutions for the many challenges our customers face, whether it’s development of low solubility drugs in their pipeline, repositioning existing drugs for better therapeutic performance or rebranding them using innovative dosage forms,’ said Amit Patel, President, Capsugel DFS.
‘Through Capsugel’s historical investments and our recent acquisition of Encap Drug Delivery, the Lipidex platform represents the industry’s most comprehensive and vertically integrated offering in the lipid, liquid and semi-solid arena. It spans polymer science and process engineering at the capsule level, as well as API handling, dosage formulation development using expert systems, clinical trial quantity supply and commercial manufacturing.’
Rounding off the Lipidex platform is the company’s network of dedicated small-scale and commercial manufacturing sites in the US, Europe and Japan. The firm says this global manufacturing footprint assures business continuity planning and includes FDA and MHRA accreditation, and specialist capability in high potency actives, controlled substances and hormones.
No comments:
Post a Comment